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ABSTRACT
Background. The efficacy of sentinel lymph node (SLN)
surgery requires targeted removal of first-draining nodes;
however, frequently more nodes are removed than necessary.
[99mTc]tilmanocept (TcTM) is a molecular-targeted radio-
pharmaceutical specifically designed for SLN mapping. We
evaluated technical outcomes of SLN biopsy in breast cancer
patients mapped with TcTM ? vital blue dye (VBD) versus
filtered [99mTc]sulfur colloid (fTcSC) ? VBD.
Methods. There were 84 versus 115 patients in the TcTM
versus fTcSC cohorts, respectively. Main measures were
the number of SLNs removed per patient and factors
influencing number of nodes removed. We also evaluated
whether the radiotracer injected affected the proportion of
positive nodes removed in node-positive patients.
Results. Fewer nodes were removed among patients
mapped with TcTM compared to fTcSC (mean TcTM: 1.85
vs. fTcSC: 3.24, p \ 0.001). Logistic regression analysis
adjusted for tumor characteristics showed that injection of
fTcSC (p \ 0.001) independently predicted removal of
greater than 3 nodes. A similar proportion of patients was
identified as node-positive, whether mapped with TcTM or
with fTcSC (TcTM: 24 % vs. fTcSC: 17 %, p = 0.3);
however, TcTM detected a greater proportion of positive
nodes among node-positive patients compared with fTcSC
(0.73 vs. 0.43, p = 0.001).
Conclusions. Patients undergoing SLN biopsy with TcTM
required fewer SLNs to identify the same rate of node-
positive patients compared with fTcSC in breast cancer
patients with similar risk of axillary metastatic disease.
These data suggest that a molecularly targeted mechanism
of SLN identification may reduce the total number of nodes
necessary for accurate axillary staging.
The efficacy of sentinel lymph node (SLN) biopsy
to accurately assess the pathologic status of the axilla while
removing minimal nodes depends on the ability of a
mapping agent to identify only clinically relevant (i.e., first
draining) nodes.1 Limitations with current standard map-
ping agents are related to their particulate nature and
include persistent radioactivity at the site of injection
interfering with precise SLN identification and radiolabel-
ing of higher echelon nodes.1,2 These limitations contribute
to lower accuracy rates and removal of unnecessary
nodes.3–7
[99mTc]tilmanocept (TcTM) is a receptor-targeted
radiopharmaceutical that was designed to improve the
specific targeting of SLNs. It is a small synthetic molecule
(molecular diameter 7.1 nm) that accumulates in lymphatic
tissue by binding mannose receptors (CD206) expressed on
reticuloendothelial cells within lymph nodes.8 The small
size allows for more rapid clearance from its injection site
compared with radiolabeled sulfur colloid, and its specific
binding to lymphatic tissue allows for sustained SLN
uptake in first echelon nodes.2,9–11 TcTM received FDA
approval in May 2013.
In this study, we compared the technical and pathologic
outcomes among clinically node-negative breast cancer
patients who underwent SLN biopsy with TcTM ? vital
blue dye (VBD) vs. filtered [99mTc]sulfur colloid
(fTcSC) ? VBD at a single institution. We evaluated
whether the choice of radiotracer affected the rate of
identified node-positive patients, the number of excised
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All breast cancer patients who underwent SLN biopsy at
UCSD with TcTM as part of two highly similar clinical
trials (June 2008–June 2009; July 2010–April 2011) were
identified from a prospectively maintained database.12 A
comparison cohort was comprised of consecutive breast
cancer patients undergoing SLN biopsy with TcSC during
the 1-year period that succeeded conclusion of the later
trial (March 2011–March 2012). The UCSD institutional
review board approved a retrospective review of patient
data for this study. Inclusion criteria included female
patients with biopsy-proven invasive breast cancer who had
SLN biopsy as part of their primary surgical procedure.
Patients with known axillary lymph node metastasis before
surgery, patients with T4 or inflammatory breast cancer,
patients who received neoadjuvant chemotherapy, and
patients with a history of prior breast or axillary surgery
were excluded from analysis. Additionally, because all
patients mapped with TcTM received intraoperative
injection of VBD in addition to radiotracer injection as part
of the clinical trial design, patients mapped exclusively
with TcSC without VBD were eliminated from analysis.
Procedures
Patients received 0.5 mCi of TcTM or 0.5 mCi of
fTcSC by intradermal injection overlying the tumor or
biopsy site. All SLN biopsy operations were performed
within 1–12 h of radiopharmaceutical injection using
standard technique by one of two surgeons, each of whom
have more than 10 years of SLN biopsy experience. Before
skin incision, patients underwent an intradermal injection
of 2–4 ml of isosulfan blue dye (Lymphazurin, US Surgical
Corporation, Norwalk, CT, USA) around the primary
tumor or biopsy site. Sentinel nodes were defined as any
blue or hot node. Hot nodes were considered any node
greater than 50 counts per 2 s and greater than 10 % of the
node with the highest count rate. Nodes that were hard or
suspicious also were removed and deemed as SLN
regardless of radioactivity or blue dye. The number of
SLNs per patient was recorded according to the surgeon-
determined count in the operating room. All removed
lymph nodes were sent to pathology for hematoxylin and
eosin staining and immunohistochemical analysis. A
positive sentinel node was defined as any SLN that con-
tained metastasis [0.2 mm.
Demographic and clinicopathologic characteristics
obtained from retrospective UCSD chart review included
year of diagnosis, age at diagnosis, race, body mass index
(BMI), primary tumor size, tumor location, histologic
subtype (ductal, lobular, mixed/tubular), tumor grade
(modified-bloom Richardson grade), estrogen and proges-
terone receptor (ER/PR) and Her2/Neu (Her2) status, and
presence of lymphovascular invasion (LVI). Lymph node
characteristics included the number of SLN removed
(surgeon count) and the number of positive SLN removed
(metastasis [2 mm).
Statistical Analysis
Patients were analyzed according to use of TcTM or
fTcSC for node mapping. Chi square analysis or Fisher’s
exact test was used to compare demographic and clinico-
pathologic factors between groups. Factors related to
number of nodes (B3 vs. [3) removed were examined
using multivariate logistic regression. We included in the
model all factors significant in univariate v2 tests at
p \ 0.1. Wilcoxon rank-sum tests were used to compare
the two groups regarding the total number of nodes
removed and the proportion of positive nodes removed
among node-positive patients.
We further used a zero-inflated negative binomial
(ZINB) model to compare the probability of a patient being
node positive and also the fraction of positive nodes among
those removed, for node-positive patients, after adjusting
for other factors.13–15 A ZINB model incorporates two
components: (1) logistic regression (the zero component of
the model) is used to assess the probability that a patient
has at least one node removed based on clinicopathologic
factors; and (2) a negative binomial model (the count
component of the model) compares the proportion of
positive nodes among all removed nodes, for node-positive
patients. To fit an adjusted model, a covariate was con-
sidered for the final model if the ‘‘univariate’’ p value from
a likelihood ratio test with 2 degrees of freedom was
\0.05. A manual backwards selection procedure was used
to reduce the models. Bootstrapped confidence intervals on
the parameter estimates were calculated based on 5,000
randomly bootstrapped samples. All tests were two-tailed
with significance level p \ 0.05 and computed using R
software (v 2.15.2, 2012, www.r-project.org).
RESULTS
Patient Population
A total of 84 women with invasive breast cancer who
participated in the combined Phase III TcTM clinical trials
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and 115 women undergoing SLNB with TcSC at UCSD in
the 12-month period after the conclusion of the second trial
met the inclusion criteria and were injected with both
radiotracer and VBD. Patient and tumor characteristics of
the two groups are presented in Table 1. There were no
significant differences in mean age or pathologic factors
between groups, although the fTcSC cohort appeared to
have slightly larger tumors.
Intraoperative Node Identification and Pathology
Findings
The intraoperative identification rate of axillary SLNs
was 100 % for both groups. On average, the TcTM cohort
had significantly fewer SLNs removed per patient com-
pared with the fTcSC group [1.85 ± 0.78 (range 1–4) vs.
3.24 ± 1.62 (range 1–10), p \ 0.001]. Figure 1 shows the
distribution of the number of SLNs removed per patient
according to radiotracer used (the mapping sensitivity). In
the TcTM group, 96 % of patients had 3 or fewer nodes
removed and no patient had more than 4 nodes removed.
By comparison, nearly 20 % of patients in the TcSC cohort
had more than 4 nodes removed. To investigate whether
clinicopathologic factors might have accounted for differ-
ences in the number of nodes removed, a logistic regression
model with outcome[3 SLNs removed confirmed that the
fTcSC group was more likely to have more than 3 nodes
removed even adjusting for these factors (p \ 0.001).
Apart from younger age, which appeared to be inversely
associated with having a higher number of SLNs removed
[odds ratio (OR) = 0.41 for age [60 vs. B60, 95 %
CI = (0.19, 0.89)], no other factors were associated with
number of nodes removed.
Although there were fewer SLNs removed in the
TcTM group, pathology analysis indicated that
[99mTc]tilmanocept and fTcSC exhibited similar sensi-
tivity for detecting positive nodes (Fig. 2). The average
number of positive nodes detected was 0.3 (95 % CI
0.16–0.43) for TcTM versus 0.23 (95 % CI 0.11–0.36)
for fTcSC. There were slightly more patients identified
with axillary metastasis in the TcTM cohort compared
with the fTcSC group [20/84 (24 %, 95 % CI 0.15–0.33)
of the patients vs. 20/115 (17 %, 95 % CI 0.11–0.25),
TABLE 1 Clinicopathologic factors in clinically node-negative














T1 61 (73) 74 (64)
T2 22 (11) 33 (29)
T3 1 (5) 8 (7)
Tumor histology 0.47
IDC 48 (57) 72 (63)
ILC 11 (13) 9 (8)
Mixed (IDC ? ILC)/
other
25 (30) 34 (29)
ER status 0.52
Positive 75 (89) 98 (85)
Negative 9 (11) 17 (15)
PR status 0.18
Positive 68 (81) 83 (72)
Negative 16 (19) 32 (28)
Her-2neu status 0.85
Amplified 14 (17) 18 (16)
Unamplified 70 (83) 97 (84)
Triple negative 0.22
Yes 5 (6) 14 (12)
No 79 (94) 101 (88)
Tumor grade (MBR) 0.25
1 32 (38) 42 (35)
2 28 (33) 50 (43)
3 24 (29) 23 (20)
LVI 0.73
Present 17 (20) 26 (23)
Absent 67 (80) 89(77)
Surgery 0.33
Lumpectomy 66 (79) 83 (72)
Mastectomy 18 (21) 32(28)
fTcSc filtered-[99mTc] sulfur colloid, IDC invasive ductal carcinoma,
ILC invasive lobular carcinoma, MBR Modified-Bloom Richardson










2 3 4 5 6













7 8 9 10
FIG. 1 SLN mapping with [99mTc]tilmanocept/VBD (blue bars)
resulted in the removal of fewer total lymph nodes compared to
fTcSC/VBD (yellow bars)
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p = 0.4]. The overall axillary metastasis rate among
patients was 42 of 203 (20.7 %).
Among those with axillary metastasis (i.e., at least one
detected positive node) in the TcTM group, a larger pro-
portion of removed nodes were found to be positive
[# positive nodes divided by # nodes removed for each
patient: 0.73 (95 % CI 0.6–0.86, n = 20) for TcTM vs.
0.43 (95 % CI 0.32–0.54, n = 20) for fTcSC]. Thus, the
rate of positive nodes among those removed was approxi-
mately 1.7 times greater (0.73/0.43 = 1.7) for TcTM
compared with fTcSC.
To investigate the statistical significance of these
observations after adjusting for clinical and pathological
factors, we used a ZINB model, which models the proba-
bility of having positive node status using logistic
regression, and then models the number of positive nodes
among those patients who were node-positive using a
negative binomial model, in a compound likelihood. This
adjusted analysis confirmed a significantly higher rate of
positive nodes among removed nodes for the patients
mapped with TcTM compared with fTcSC (adjusted rate
ratio = 5.52, 95 % CI 2.46, 12.39, p \ 0.001). In addition,
among all the covariates considered, the ZINB model
showed that LVI status [odds for being node-negative for
presence vs. absence = 0.03 (95 % CI, 0.0034–0.27)] and
tumor size [odds for being node-negative for those with T2
or T3 vs. T1 = 0.11 (95 % CI, 0.018–0.61)] were inde-
pendent predictors for having any positive SLN.
DISCUSSION
SLN biopsy is widely accepted in breast cancer sur-
gery; however, false-negative rates in modern practice
range up to 10 %; and the number of SLNs removed
varies based on surgeon and tumor-related factors, with
frequent removal of unnecessary nodes.3,4,6,16 Ideally,
only the anatomically sentinel node(s) would be removed.
Technetium 99m-tilmanocept (TcTM) is a receptor-tar-
geted radiopharmaceutical that binds specificity to
macrophages (CD-206 receptor) and was designed with
the aim to achieve superior SLN-targeting during preop-
erative lymphoscintigraphy and intraoperative SLN
identification.8,17 It remains to be determined whether
improved targeting of these clinically relevant nodes can
simultaneously improve biopsy accuracy and also limit
the number of nodes removed.
In the current study, we found that on average signifi-
cantly fewer SLNs were removed in patients mapped with
TcTM ? VBD compared with patients mapped with
fTcSC ? VBD (average number of nodes removed, 1.85
vs. 3.24, respectively). In the TcTM group, 96 % of
patients had 3 or fewer nodes removed and no patients had
more than 4 nodes removed. By comparison, nearly 20 %
of patients in the TcSC cohort had more than 4 nodes
removed. This rate is consistent with prior series evaluating
the number of SLNs removed with various preparations of
TcSC, where the reported ranges vary from 1–8 to 1–13
SLNs, and in 20 % of patients, more than 4 nodes are
removed.4,18
Removal of fewer SLNs might potentially decrease
patient morbidity. For example, the American College of
Surgeons Oncology Group Z0010 trial (ACOSOG Z0010)
found that a high number of SLNs removed ([5) was
associated with increased incidence of seromas and infec-
tion.19 Additionally, removing fewer SLNs may lower the
operative time and pathology cost of the procedure.7
However, removal of fewer nodes is not justified if diag-
nostic accuracy is not maintained. The minimal number of
SLNs necessary for accurate axillary staging is heavily
debated.4–6,18,20,21 Many authors have observed that
removing a larger number of SLN(s) improves biopsy
accuracy and that up to 4–5 nodes are needed in some
patients to achieve acceptable false negative rates.18,20,22,23
It is important to consider that the removal of many
nodes in a patient implies the removal of some higher
echelon nodes.1,24–26 In order to study factors that may
influence removal of nonsentinel nodes, we analyzed pre-
dictors of removal of more than 3 SLNs, using multivariate
logistic regression. The threshold of 3 was based on studies
evaluating lymphatic drainage of the breast, which dem-
onstrate there are generally at most 3 parallel draining
pathways from the breast.24–26 Therefore, removal of more
than 3 SLNs implies identification of nodes that are ana-
tomically nonsentinel. These nodes would not hold the
same predictive capacity as first-draining nodes and thus
can be clinically confusing when analyzed in the setting of
SLN biopsy. The worst-case consequence of downstream
node labeling is that a true anatomically sentinel node

























FIG. 2 [99mTc]tilmanocept (blue bars) and fTcSC (yellow bars)
exhibited similar numbers of positive SLN detected, among those
removed
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identification of ‘‘hot nodes’’ intraoperatively (which are
truly higher echelon nodes). Thus, removal of a larger
number of nodes alone would not necessarily improve
biopsy accuracy, because it might lead to suboptimal tar-
geting of first-draining nodes.
In our study, the decrease in number of nodes removed
among patients mapped with TcTM did not come at the
expense of a lower rate of detection of node-positive patients.
A similar proportion of node-positive patients were observed
in the TcTM cohort and the fTcSC cohort (24 vs. 17 %). This
would be expected, as our populations were fairly homoge-
nous in important clinicopathologic factors.
Importantly, despite removal of fewer total nodes by
TcTM, the number of positive nodes removed per patient
was very similar for the two radiotracers and was 0.3 for
TcTM versus 0.26 for fTcSC. Considering only node-
positive patients, the proportion of positive nodes among
nodes removed was approximately 1.7 times greater
(observed relative risk [RR] = 0.73/0.43 = 1.7) for TcTM
compared with fTcSC. After adjusting for clinical and
pathologic factors in a ZINB model, we found that TcTM
remained significantly more likely to discover a positive
node among the nodes removed. Because the model takes
into account both the risk of node positivity and the pro-
portion of positive nodes among the number of nodes
removed, the clinical relevance is that fewer nodes were
necessary to detect metastasis and that overall, nodes
removed in the TcTM held greater predictive value. This
would support the theory that there is improved targeting of
the clinically relevant nodes in the TcTM group.
In our study, all patients were mapped with a dual-agent
method (radiotracer ? VBD), and we do not discriminate
in our study between SLNs that were only hot versus only
blue or both. However, because VBD was common to both
radiotracer groups, it would follow to attribute technical
differences to the radiolabeled agent. Additionally, many
factors may influence the number of SLNs and although we
controlled for some, many factors were not controlled for
by nature of retrospective comparison (such as multiple
radiologists performing injections, slight variance in tech-
nique). However, the most important determinant of
number of SLNs removed at surgery is related to surgeon
skill/experience, which is well controlled for in our study
in that only two surgeons, each with more than 10 years of
SLN surgery experience, performed all the surgeries.1
Finally, as aforementioned, it is impossible to evaluate the
accuracy fully without performing a completion node dis-
section and calculating an FNR, which we did not do in our
study. We provide compelling evidence for greater sensi-
tivity for finding positive nodes with our ZINB mode;
however, larger studies and evaluation of FNR In patients
with cancers where SLN biopsy is not yet standard of care
will more directly evaluate relative accuracy between
agents. This is currently being done in a recently completed
Phase III clinical trial evaluating the use of TcTM for
SLNB in oral cavity squamous cell carcinoma.27 Technical
outcomes of this trial were recently presented and con-
trasted to results from a prospective study of SLNB in SCC
using TcSC. This study found TcTM provided improved
overall accuracy (AC) and decreased FNR compared with
TcSC (AC: 99 vs. 97 %, p = 0.02; FNR: 3 % vs. 10 %,
p \ 0.001, for TcTM and TcSC respectively).28 Thus,
these results are consistent with the theory of maintained or
improved staging accuracy with use of TcTM.
CONCLUSIONS
We compared breast cancer patients undergoing SLN
biopsy at a single institution as part of TcTM Phase III
clinical trials to a similar cohort of patients undergoing
SLN biopsy with fTcSC. We found that significantly fewer
SLNs were removed on average in patients mapped with
TcTM ? VBD compared with those patients mapped with
TcSC ? VBD. However, TcTM ? VBD identified a sim-
ilar proportion of node-positive patients, and the number of
positive nodes removed using the two radiotracers also was
very similar. Our data suggest that a molecular-based
mechanism of SLN identification may produce superior
targeting of the true SLN(s) and thus reduce the total
number of nodes necessary for accurate axillary staging in
early stage breast cancer patients.
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